Sienna Biopharmaceuticals Completes $34 Million Series A Financing

Sienna Biopharmaceuticals, Inc., a development stage company focused on aesthetics and medical dermatology, completed a $34 million Series A financing led by ARCH Venture Partners. Additional investors included Altitude Life Science Ventures, Partner Fund Management, and Venvest Capital, as well as direct investment by several prominent aesthetics and medical dermatology industry luminaries. Sienna Biopharmaceuticals’ mission is to bring to market innovative new products that have the potential to improve patient outcomes and advance the practice of medicine in aesthetics and medical dermatology. The Company brings together the leadership and executive team from Kythera Biopharmaceuticals, Inc., recently acquired by Allergan, and the backing of several investors who supported the growth and success of Kythera. Leading the Company is Frederick C. Beddingfield III, MD, PhD, as President and CEO, and Keith Leonard, as Executive Chairman.

Sienna Biopharmaceuticals’ lead proprietary technology, Silver Plasmonic Therapy (SPT), has promising applications for acne and permanent hair removal. Clinical trials are already underway and the Company is evaluating additional potential indications.

“We are pleased with the opportunity to partner with high-quality investors who share our vision of bringing innovative new products to market in aesthetics and medical dermatology,” said Frederick C. Beddingfield III, M.D., Ph.D., President and CEO of Sienna Biopharmaceuticals. “With this proven team and financing, we have a strong foundation from which we can advance our SPT technology and further our efforts in building a pipeline of early- to late-stage novel assets. All the pieces are in place to create the next great company in aesthetics and medical dermatology.”

“Given the current changing corporate landscape and disruption in the dermatology space, we believe the timing is right for a company focused on innovation in aesthetics and medical dermatology. Sienna Biopharmaceuticals combines a world class team with proven abilities in R&D and commercialization and strong financial backing,” said Keith Leonard, Executive Chairman of Sienna Biopharmaceuticals and previously the CEO of Kythera.

The Sienna Biopharmaceuticals’ Board of Directors bring together biopharmaceutical industry leaders with extensive experience in aesthetics and dermatology, finance and business formation and growth. The members of the Sienna Board of Directors are:

Keith R. Leonard, Jr. – Executive Chairman, Sienna

Frederick C. Beddingfield, III, MD, PhD – President and CEO, Sienna

Kristina Burow – Managing Director, ARCH Venture Partners

Todd Harris, Ph.D. – Head of Corporate Development, Sienna

Bob Moore, MBA – Chairman, One Revolution

Robert Nelsen – Managing Director, ARCH Venture Partners